N. Ewing

发表

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

V. Ramanan, P. Mannucci, F. Rosendaal, 2016, The New England journal of medicine.

Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010

J. Oldenburg, A. Federici, N. Ewing, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Bacteria, arthritis, and skin lesions due to Kingella kingae.

G. Overturf, N. Ewing, D. Redfield, 1980, Archives of disease in childhood.

Cerebral vasculopathy in sickle cell anemia: diagnostic contribution of positron emission tomography.

C. Zee, P. Conti, N. Ewing, 1999, Blood.

Venous Thromboembolism Risk Assessment and Prophylaxis Use in Pediatric, Adolescent, and Young Adult Hematology Oncology Patients

W. Landier, N. Ewing, M. Hockenberry, 2015, Journal of pediatric hematology/oncology.

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

C. Kempton, C. Kessler, B. Ritchie, 2007 .

Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A

L. Valentino, M. Recht, M. Simmons, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

von Willebrand factor: what is its role in the immune response in haemophilia?

P. Mannucci, S. Kaveri, C. Kessler, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Newborn diagnosis of abnormal hemoglobins from a large municipal hospital in Los Angeles.

N. Ewing, W. Schroeder, D. Powars, 1981, American journal of public health.

Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors.

N. Ewing, C. Kasper, C. Kasper, 1988, JAMA.

Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols.

G. Mariani, N. Ewing, C. Kasper, 1994, Seminars in hematology.

In vitro detection of mild inhibitors to factor VIII in hemophilia.

N. Ewing, C. Kasper, 1982, American journal of clinical pathology.

The application of bypassing‐agent prophylaxis in haemophilia A patients with inhibitors: a meeting report

L. Valentino, C. Leissinger, V. Blanchette, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors

C. Escuriola-Ettingshausen, N. Ewing, W. Kreuz, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors

L. Valentino, C. Leissinger, N. Ewing, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Consequences of switching from prophylactic treatment to on‐demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study

T. Humphries, M. Tarantino, N. Ewing, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Hematologic management of hemophilia A for surgery.

J. Luck, N. Ewing, C. Kasper, 1985, JAMA.

Identifying non‐responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition

C. Négrier, G. Young, P. Collins, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Therapeutic choices for patients with hemophilia and high‐titer inhibitors

M. Poon, L. Aledort, E. Berntorp, 2001, American journal of hematology.

Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators

M. Wilkerson, C. Königs, C. Dalgard, 2019, Frontiers in Immunology.

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Miguel Ángel Martínez, P. Mannucci, E. Santagostino, 2015 .

Consequences of Switching From Prophylactic Treatment to On-Demand Treatment in Late Teens and Early Adults with Severe Hemophilia A. the TEEN/TWEN Study

T. Humphries, N. Ewing, M. Manco‐Johnson, 2011 .

Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors.

N. Ewing, 1990, Progress in clinical and biological research.

Comparative efficacy of nonheated and heat‐treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors

N. Ewing, R. Schwartz, J. Spero, 1989, American journal of hematology.

Induction of Immune Tolerance, the Future of the Registry

N. Ewing, 1996, Vox sanguinis.

Dr. Nadia Ewing Responds

N. Ewing, 1981 .

Neutrophilic phagocytosis in autoimmune thrombocytopenia purpura

N. Ewing, D. Powars, G. Marshall, 1982, The American journal of pediatric hematology/oncology.

Altered distribution of T-lymphocyte subpopulations in lymph nodes from patients with acquired immunodeficiency-like syndrome and hemophilia.

C. Taylor, J. Parker, N. Ewing, 1983, The Journal of pediatrics.

Erratum: Therapeutic choices for patients with hemophilia and high-titer inhibitors (American Journal of Hematology (2001) 67 (240-246))

M. Poon, L. Aledort, E. Berntorp, 2002 .

Induction of Immune Tolerance in Hemophiliacs With Inhibitors-Reply

N. Ewing, C. Kasper, N. L. Sanders, 1988 .

Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease

R. Watts, E. Kraut, B. Kerlin, 2009, Haemophilia.